Small Cell Lung Cancer (SCLC)

FDA Grants Traditional Approval to Tarlatamab-dlle for ES-SCLC After Phase 3 Survival Benefit

The FDA has granted full approval to Tarlatamab-dlle (Imdelltra) for patients with extensive-stage small-cell lung cancer progressing after platinum therapy. Phase 3 DeLLphi-304 data showed...

Latest Post

FDA Approves First Maintenance Therapy for ES-SCLC: Lurbinectedin Plus Atezolizumab Extends Survival in IMforte Trial

FDA approves lurbinectedin plus atezolizumab for ES-SCLC maintenance, extending OS to 13.2 months vs 10.6...

Ideaya Advances Precision Oncology Pipeline with Positive Data from Three Cancer Drug Candidates

Ideaya presents promising data across three cancer drugs: darovasertib (76% response), IDE849 (58% response), and...

Histology Drives Lung Cancer Screening Effectiveness: Major Analysis of NELSON and NLST Trials

Screening effectiveness varies by histology, with adenocarcinoma showing 17.8-23.0% mortality reduction across trials.

DLL3 Trispecific Antibody Enhances T-Cell Infiltration in SCLC Through Novel CD3/CD137 Dual Targeting

Novel DLL3 trispecific antibody combines CD3 activation with CD137 costimulation to enhance T-cell infiltration in...

FDA Grants Breakthrough Therapy Designation for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer

FDA grants breakthrough therapy designation to ifinatamab deruxtecan for pretreated extensive-stage small cell lung cancer...

Lung Cancer Insight Center

Non-Small Cell Lung Cancer (NSCLC)

About
Contact
Privacy Policy
Terms of Use

About
Contact
Privacy Policy
Terms of Use

732-455-2192
contact@oncologynexus.com

Facebook-f Twitter Google-plus-g Pinterest